OPKO Health Inc
NASDAQ:OPK
Operating Margin
OPKO Health Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
OPKO Health Inc
NASDAQ:OPK
|
1.1B USD |
-44%
|
||
FR |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
||
US |
Abbvie Inc
NYSE:ABBV
|
311.5B USD |
28%
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
143.5B USD |
19%
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
112.2B USD |
38%
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
106.1B USD |
40%
|
||
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
CSL Ltd
ASX:CSL
|
135.3B AUD |
26%
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
76.5B USD |
30%
|
||
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
NL |
argenx SE
XBRU:ARGX
|
38.2B EUR |
-15%
|
OPKO Health Inc
Glance View
In the bustling world of healthcare and biotechnology, OPKO Health Inc. stands as a unique and dynamic player. Founded by the ambitious mind of Dr. Phillip Frost, the company has woven itself into the fabric of diverse biomedical sectors. OPKO predicates its enterprise on the integration of complementary businesses ranging from diagnostics to pharmaceuticals, creating synergies that are not just theoretical, but markedly operational. At the heart of its operations lies the interplay between new drug discovery and diagnostics development, allowing OPKO to leverage cutting-edge technologies in crafting novel health solutions. By honing in on significant medical unmet needs, they aspire to deliver innovations that address chronic diseases such as diabetes, oncology, and neurological disorders. This strategic weaving together of distinct healthcare sectors manifests in OPKO's sprawling portfolio—from the renowned Rayaldee, which targets secondary hyperparathyroidism, to its advanced diagnostics segments, which include proprietary tests for specific cancers and other conditions. The company's revenue streams can be best visualized as an interlocking lattice of healthcare services and products. It earns through a blend of product sales, licensing, and collaborative agreements with other biotech and pharmaceutical giants. Rayaldee, as a potent testament to their R&D prowess, contributes robustly to their revenue, while the diagnostics division, powered by their substantial investment in technology and infrastructure, brings in consistent sales from various testing services. The company’s BioReference Laboratories, one of the largest full-service diagnostic laboratories in the U.S., also plays a critical role in their financial architecture, offering both routine and esoteric tests. Additionally, OPKO is involved in strategic collaborations and licensing arrangements, enhancing its market footprint and creating channels for revenue infusion through partnerships with industry leaders. Ultimately, OPKO Health Inc.'s narrative is one of leveraging diversified capabilities and strategic partnerships to carve out a formidable presence in the complex landscape of global healthcare.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on OPKO Health Inc's most recent financial statements, the company has Operating Margin of -43.5%.